Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA...
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung...
BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue PR Newswire BERGEN, Norway, May 26, 2023 NOT FOR RELEASE...
BerGenBio ASA: Proposed partially underwritten rights issue PR Newswire BERGEN, Norway, April 25, 2023 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY...
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11...
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11...
BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update PR Newswire BERGEN, Norway, Feb. 16, 2023 BERGEN, Norway...
BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients PR Newswire BERGEN...
BerGenBio Announces the Establishment of Oncology Scientific Advisory Board PR Newswire BERGEN, Norway, Feb. 2, 2023 - Distinguished global...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관